Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PIIIWNASDAQ:SXTPNASDAQ:TOIIW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePIIIWP3 Health Partners$0.01-2.1%$0.01$0.01▼$0.09N/AN/A30,094 shs31,649 shsSXTP60 Degrees Pharmaceuticals$2.15+3.9%$2.54$1.41▼$35.99$3.05M2.89576,357 shs70,384 shsTOIIWOncology Institute$0.06-2.9%$0.07$0.01▼$0.20N/AN/A32,382 shs6,494 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePIIIWP3 Health Partners0.00%+10.34%+3.23%-26.15%-89.21%SXTP60 Degrees Pharmaceuticals0.00%-6.33%+2.99%+11.29%+46.81%TOIIWOncology Institute0.00%+12.75%+8.83%+168.48%+206.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPIIIWP3 Health PartnersN/AN/AN/AN/AN/AN/AN/AN/ASXTP60 Degrees Pharmaceuticals3.1487 of 5 stars3.35.00.00.00.02.50.6TOIIWOncology InstituteN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePIIIWP3 Health Partners 0.00N/AN/AN/ASXTP60 Degrees Pharmaceuticals 2.50Moderate Buy$7.00225.58% UpsideTOIIWOncology Institute 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PIIIW, TOIIW, and SXTP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/2/2025SXTP60 Degrees PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.80 ➝ $7.005/24/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/10/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/24/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/8/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/28/2025SXTP60 Degrees PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPIIIWP3 Health Partners$1.49BN/AN/AN/AN/AN/ASXTP60 Degrees Pharmaceuticals$300K10.54N/AN/A($6.38) per share-0.34TOIIWOncology Institute$403.15MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePIIIWP3 Health PartnersN/AN/A0.00∞N/AN/AN/AN/AN/ASXTP60 Degrees Pharmaceuticals-$7.95M-$50.41N/AN/AN/A-1,947.30%N/A-174.90%8/13/2025 (Estimated)TOIIWOncology InstituteN/AN/A0.00∞N/AN/AN/AN/AN/ALatest PIIIW, TOIIW, and SXTP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SXTP60 Degrees Pharmaceuticals-$1.31-$1.56-$0.25-$1.56$0.15 million$0.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPIIIWP3 Health PartnersN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ATOIIWOncology InstituteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPIIIWP3 Health PartnersN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/A3.142.71TOIIWOncology InstituteN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPIIIWP3 Health PartnersN/ASXTP60 Degrees Pharmaceuticals7.96%TOIIWOncology InstituteN/AInsider OwnershipCompanyInsider OwnershipPIIIWP3 Health PartnersN/ASXTP60 Degrees Pharmaceuticals10.27%TOIIWOncology InstituteN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePIIIWP3 Health Partners500N/AN/ANot OptionableSXTP60 Degrees Pharmaceuticals31.47 million1.32 millionNot OptionableTOIIWOncology Institute660N/AN/ANot OptionablePIIIW, TOIIW, and SXTP HeadlinesRecent News About These CompaniesThe Oncology Institute, Inc. to Join Russell 2000® and Russell 3000® Indexes After 2025 ReconstitutionJune 3, 2025 | quiverquant.comOncology Institute Explores PIPE Financing OpportunityMay 19, 2025 | tipranks.comWhy The Oncology Institute, Inc. (TOI) is Surging in 2025April 30, 2025 | insidermonkey.comThe Oncology Institute, Inc. (NASDAQ:TOI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | insidermonkey.comOncology Institute, Inc. Prepares for PIPE FinancingMarch 24, 2025 | tipranks.comThe Oncology Institute, Inc. Announces $16.5 Million Private Placement AgreementMarch 24, 2025 | quiverquant.comThe Oncology Institute, Inc. Scheduled to Release Q4 and Full Year 2024 Financial Results on March 25, 2025March 4, 2025 | quiverquant.comTOI Stock Earnings: The Oncology Institute Misses EPS, Misses Revenue for Q2 2024August 13, 2024 | investorplace.comTOI Stock Earnings: The Oncology Institute Misses EPS, Beats Revenue for Q4 2023March 27, 2024 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePIIIW, TOIIW, and SXTP Company DescriptionsP3 Health Partners NASDAQ:PIIIW$0.0094 0.00 (-2.08%) As of 02:09 PM EasternP3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.60 Degrees Pharmaceuticals NASDAQ:SXTP$2.15 +0.08 (+3.86%) Closing price 04:00 PM EasternExtended Trading$2.09 -0.06 (-2.60%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.Oncology Institute NASDAQ:TOIIW$0.06 +0.00 (+0.33%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
